NTRK1 and cancer: Several TRK inhibitors, including Entrectinib [20], Larotrectinib [21] or Repotrectinib [22, 23], have shown impressive responses in cancers with rearranged NTRK, including lung, colorectal, thyroid, neuroblastoma, gastric carcinoma, and pediatric cancers.